The outbreak is outpacing the response, and the true scale remains hidden.
In the eastern Democratic Republic of Congo, a rare and lethal strain of Ebola called Bundibugyo is spreading faster than the systems built to contain it. With 933 confirmed cases and at least 245 deaths — numbers that almost certainly undercount the true toll — frontline medical workers are confronting not a failure of will, but a failure of infrastructure: too few labs, too little equipment, too many communities unreachable by the tools that exist. This outbreak has already surpassed every previous Bundibugyo event in recorded history, and without urgent investment in diagnostics, surveillance, and community trust, it may continue unchecked for a year or more.
- A Bundibugyo Ebola strain with no vaccine and no cure is killing between 30 and 50 percent of those it infects, and the true case count is almost certainly far higher than official figures suggest.
- Testing bottlenecks are catastrophic — samples take weeks to reach the handful of labs capable of processing them, and rapid tests designed for other Ebola strains cannot reliably detect this one.
- Conflict, displacement, and mining routes are accelerating transmission across remote areas while healthcare workers face attacks from armed groups and overwhelmed communities gripped by fear and rumor.
- The outbreak has already exceeded the scale of all previous Bundibugyo events, yet the number of expert medical organizations on the ground remains dangerously small relative to the need.
- Responders are pressing for decentralized testing, mobile laboratories, safe burial messaging, and deep community engagement — but establishing even basic infrastructure will take months the outbreak may not allow.
Before dawn each day, an MSF emergency coordinator named Dierberg arrives at her post in eastern DRC and does not leave until long after dark. Her teams rotate through twelve-hour shifts. Sleep comes when the patient load allows. She is watching an epidemic move faster than anyone can measure it.
The outbreak involves Bundibugyo, a rare Ebola strain that kills between three and five of every ten people it infects. There is no vaccine and no cure. By mid-June, the health ministry had confirmed 933 cases and at least 245 deaths — but Dierberg and her colleagues believe those numbers are too low. In remote areas torn by conflict and mining activity, cases go undetected. Deaths that might be Ebola are recorded as something else. The true scale remains hidden.
The obstacle is not negligence. It is infrastructure. Confirming a Bundibugyo case requires a specific PCR test available only in a handful of specialized laboratories. Samples from remote areas can take weeks to arrive. Rapid tests exist, but they were designed for a different Ebola species and cannot detect this strain until viral load is dangerously high. MSF's emergency programme manager Trish Newport describes the situation plainly: hundreds of samples sit untested, new suspected cases arrive daily, and the diagnostic cartridges that might help do not fit the equipment already in place.
This outbreak has already surpassed the scale of previous Bundibugyo events in Uganda and the DRC. Yet the response remains thin. Healthcare workers treating patients also face attacks from community members and armed groups. The DRC has real experience with Ebola — surveillance systems, laboratory capacity, clinical care built over years — but that infrastructure was already fragile before this virus arrived, and international funding cuts have weakened it further.
The outbreak may have begun with a pastor whose casket broke at a crowded funeral — a single moment that may have seeded the epidemic. Now safe burial messaging is critical, and community trust is the weakest link. In areas already marked by conflict and food insecurity, rumors spread faster than facts.
Dierberg sees no major improvement in the next six to twelve months unless vaccines and treatments emerge from laboratories working on them now. What would make the greatest difference, she says, is not heroic intervention but foundational work: stronger surveillance, expanded diagnostics, mobile laboratories, rapid isolation of suspected cases, and genuine investment in the communities that must ultimately be partners in stopping this.
In the eastern Democratic Republic of Congo, a doctor named Dierberg arrives at her post before dawn and leaves long after sunset, rotating her teams through twelve-hour shifts to keep the facility running around the clock. Sleep comes when the patient load allows it. She is an emergency medical coordinator with Médecins Sans Frontières, and she is watching an epidemic accelerate faster than anyone can track it.
The outbreak involves a rare strain of Ebola called Bundibugyo, which kills between three and five of every ten people it infects. There is no vaccine. There is no cure. As of mid-June, the health ministry had confirmed 933 cases and at least 245 deaths in the eastern provinces. But Dierberg and her colleagues know those numbers are almost certainly too low. Without adequate testing capacity, deaths that look unrelated might actually be Ebola. Cases in remote areas, in places torn by conflict and mining operations, go undetected. The true scale of the outbreak remains hidden.
The problem is not ignorance or negligence. It is infrastructure. Confirming a Bundibugyo case requires a specific PCR test, available only in a handful of specialized laboratories. In remote areas, samples can take weeks to reach a lab. By then, the person may have infected others, or died, or both. There are no rapid tests designed for this strain—the rapid tests that exist were built for a different Ebola species and cannot detect the virus until a person's viral load is dangerously high. Trish Newport, an emergency programme manager for MSF, describes the shortage plainly: hundreds of samples sit untested. New suspected cases arrive daily. The cartridge-based assays that might help do not fit the equipment already in place. Establishing decentralized testing will take months, maybe longer.
The outbreak has already exceeded the scale of previous Bundibugyo outbreaks in Uganda in 2007 and 2008, and in the DRC itself in 2012. Yet the response on the ground remains thin. Newport says the number of expert medical organizations actually present is far too small, and what support exists falls short of what is needed. Dierberg's teams are not only treating patients and managing logistics—they are training healthcare workers, many of whom face attacks from community members or armed groups. Protection is non-negotiable, even when medicines run short and the burden of care is crushing.
The DRC is not starting from nothing. The country has experience with Ebola surveillance, vaccination campaigns, laboratory work, and clinical care built up over years. But that infrastructure is straining under the weight of this outbreak, and it was already fragile before the virus arrived. Conflict has displaced populations. Mining and trade routes move people constantly. Health systems that were already under stress have been further weakened by cuts to international funding. Surveillance systems designed to catch outbreaks early are failing to keep pace. Dierberg emphasizes what an effective system would need: permanent laboratory infrastructure and mobile labs that can reach isolated communities. It would need community trust—and right now, that is the weakest link. In areas already ravaged by conflict, displacement, and food insecurity, rumors spread faster than facts. People ask why the disease is there, why certain areas are hit harder, whether they can trust the response. Transparent communication is not optional; it is essential.
The outbreak may have begun with a pastor whose casket broke during his funeral, an event crowded with mourners. That single moment, that one broken casket, may have seeded the epidemic. Now, messaging about safe burials has become critical. Dierberg sees no major improvement in the next six to twelve months unless vaccines and treatments for Bundibugyo emerge from the laboratories working on them now. What would make the greatest difference, she says, is not heroic intervention but foundational work: strengthening surveillance systems, expanding access to diagnostics, improving laboratory capacity, supporting rapid isolation of suspected cases, and investing in genuine community engagement. These are not glamorous interventions. They are the unglamorous work of stopping an epidemic before it becomes a catastrophe.
Notable Quotes
One of our main concerns is that we do not yet have the full picture of the outbreak due to limited diagnostic capacity and likely under-reporting of cases.— Dierberg, emergency medical coordinator, Médecins Sans Frontières
The number of expert medical organisations responding on the ground is still far too limited, and the level of support being provided falls far short of what is needed.— Trish Newport, emergency programme manager, MSF
The Hearth Conversation Another angle on the story
Why does testing take so long in a place that has dealt with Ebola before?
The DRC has the experience, but not the equipment where it's needed. The test that confirms Bundibugyo requires specialized PCR machines. There are only a handful of labs with them. A sample from a remote area might travel for weeks. By then, the person is already dead or has infected others.
So the real number of cases is much higher than 933?
Almost certainly. Dierberg says cases are going undetected in remote and insecure areas. Without testing, you cannot know if a death was Ebola or something else. The outbreak is larger than the numbers suggest.
What about the rapid tests that work for other Ebola strains?
They don't work for Bundibugyo. And even the ones that do exist can't detect the virus until someone is already very sick—when their viral load is extremely high. By then, they've likely infected others.
Is the DRC just unprepared?
No. They have real experience with Ebola. But the systems are overwhelmed. Funding has been cut. Conflict keeps displacing people. Health facilities were already strained before this outbreak. And now healthcare workers are being attacked while they work.
What would actually stop this?
Dierberg says the most important thing is strengthening surveillance and early detection. Expanding diagnostics, improving lab capacity, rapid isolation of cases, and community engagement. Not heroic measures—foundational work. And vaccines, if they come in time.
How long could this continue?
Six to twelve months, she thinks, without major changes. New cases arrive daily. Hundreds of samples remain untested. The outbreak is still accelerating.